Chicago, USA – SparX is thrilled to officially unveil its groundbreaking Nano Antibody Bifunctional Biparatopic Antibody Drug Conjugate (Nab2-ADC), a pioneering development poised to revolutionize cancer therapy.
At the opening day of BIO Asia-Taiwan 2024, Dr. Gui-Dong Zhu, CEO of SparX Group, introduced the Nab2-ADC platform technology during Session 4 on ADC Drug Development and Manufacturing Trends, Challenges, and Solutions. This marked the first official release of SparX’s innovative technology, which addresses major limitations of current ADC therapies, including off-target side effects, most prominently interstitial lung disease (ILD), and suboptimal targeting efficiency.
In his presentation, Dr. Zhu detailed the evolution of the Nab2-ADC platform and the cutting-edge technologies supporting its implementation. The nanobody-based design of Nab2-ADC, coupled with its smaller molecular weight, effectively mitigates critical limitations of current ADCs. These include the risk of ILD, inadequate targeting efficiency, slow tumor penetration, and immunoglobin-driven off-target toxicity.
Nab2-ADC boasts advanced targeting efficiency by utilizing bifunctional antibodies to recognize two distinct epitopes on separate antigens, or biparatopic antibodies to bind two epitopes on the same antigen simultaneously. This design significantly enhances targeting precision. By eliminating the Fc region responsible for non-specific binding to healthy tissues expressing FcÎłR, Nab2-ADC not only improves targeting efficiency but also reduces the risk of ILD through decreased macrophage uptake in the lungs. Additionally, the nano-sized bispecific antibodies in Nab2-ADC ensure deeper and more efficient drug infiltration to the tumor microenvironment, maximizing cytotoxic effects even in hard-to-reach tumor cells.
Dr. Zhu also highlighted the powerful SparxNano™ platform for nanobody discovery, the true site-specific uniQon™ conjugation, and the Diturbo™ stable cell line development technologies. These innovations provide robust solutions for the discovery and manufacturing challenges of Nab2-ADC.
As a testament to the potential of the Nab2-ADC platform, Dr. Zhu introduced SPX-802, a first-in-class (FIC) anti-PD-L1/VEGF-DXdd2 ADC. SPX-802 demonstrates superior tumor cell internalization, efficient lung delivery via inhalation, high bioavailability of subcutaneous drug administration, and excellent in vivo efficacy in humanized tumor models.
About SparX Biopharmaceutical:
A research-driven, development-stage biopharmaceutical trailblazer, SparX Biopharmaceutical Corp. has a mission of “amplifying human immunity with groundbreaking antibody therapies.” Through the utilization of big data analytics, including machine learning, SparX decrypts potential interactions within the vast complexity of biological information. With meticulous pharmacological analyses, backed by in vitro and in vivo evaluations using advanced mouse models, SparX is on a relentless quest to develop unparalleled therapeutics. SparX’s robust target discovery platform, combined with the multifaceted SAILING™ antibody optimization system and groundbreaking bi-ADC technology, is poised to redefine the success metrics of empowered antibody drug development. Equipped with in-house cGMP facilities, SparX is on track to become a self-sustaining, fully integrated biopharmaceutical entity.
